皮卡佐剂与其治疗性疫苗作用机理.pdfVIP

Open Journal of Nature Science 自然科学, 2015, 3(3), 70-80 Published Online August 2015 in Hans. /journal/ojns /10.12677/ojns.2015.33010 Mechanisem of Action of PICKCa Adjuvant and Its Therapeutic Vaccines * Haixiang Lin , Yi Zhang Beijing Yishengxingye Science and Technology Co. Ltd., Beijing * Email: haixianglin510@ th th st Received: Jul. 27 , 2015; accepted: Aug. 14 , 2015; published Aug. 21 , 2015 Copyright © 2015 by authors and Hans Publishers Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). /licenses/by/4.0/ Abstract PICKCa, a safe vaccine adjuvant for human use, is a complex of poly IC-kanamycin-Cacl . It is the li- 2 gand of pattern recognition receptors of TLR3, NOD and RIG-1. PICKCa vaccines can activate innate pathways in vivo to produce cytokines including IFN-α, IFN-β, IFN-γ, IL-2, IL-12p40, IL-6, TNF-α, promote macrophage function, stimulate antigen-presenting cells to produce co-stimulators of CD40, CD80, CD86, activate cell-mediated immunity and humoral immunity. Due to PICKCa adjuvant en- hancing productions of IFN, IL-2, IL-12, the adjuvant may make prophylactic vaccines from main humoral immunity to possess strong cell-mediated immunity as therapeutic vaccines. In 3 indepen- dent assays of post-explosure immunizations of mice and beagle dogs, PICKCa rabies vaccine was much better than commercial adjuvant-free rabies vaccines, the protective rate was 70% - 100% and 20% - 30% respectively,